NA
ARQT icon

NewEdge Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

NewEdge Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8K Sell
500
-1,045
-68% -$26.7K ﹤0.01% 3360
2025
Q4 		$44.9K Buy
1,545
+1,045
+209% +$26.8K ﹤0.01% 2988
2025
Q3 		$9.43K Sell
500
-300
-38% -$4.73K ﹤0.01% 3342
2025
Q2 		$11.2K Buy
800
+100
+14% +$1.4K ﹤0.01% 3177
2025
Q1 		$10.9K Buy
+700
New +$9.86K ﹤0.01% 3066
2023
Q3 		– Sell
-100
Closed -$953 – 3472
2023
Q2 		$953 Hold
100
– – ﹤0.01% 3250
2023
Q1 		$1.1K Hold
100
– – ﹤0.01% 3144
2022
Q4 		$1 Buy
+100
New +$1.75K ﹤0.01% 3979

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return